Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: The BIOGRID studies

UP Rohr; P Herrmann; K Ilm; H Zhang; S Lohmann; A Reiser; A Muranyi; J Smith; S Burock; M Osterland; K Leith; S Singh; P Brunhoeber; R Bowermaster; J Tie; M Christie; HL Wong; P Waring; K Shanmugam; P Gibbs; U Stein

Journal article

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: The BIOGRID studies

UP Rohr, P Herrmann, K Ilm, H Zhang, S Lohmann, A Reiser, A Muranyi, J Smith, S Burock, M Osterland, K Leith, S Singh, P Brunhoeber, R Bowermaster, J Tie, M Christie, HL Wong, P Waring, K Shanmugam, P Gibbs Show all

Annals of Oncology | OXFORD UNIV PRESS | Published : 2017

DOI: 10.1093/annonc/mdx207

Abstract

Background: We assessed the novel MACC1 gene to further stratify stage II colon cancer patients with proficient mismatch repair (pMMR). Patients and methods: Four cohorts with 596 patients were analyzed: Charité 1 discovery cohort was assayed for MACC1 mRNA expression and MMR in cryo-preserved tumors. Charité 2 comparison cohort was used to translate MACC1 qRT-PCR analyses to FFPE samples. In the BIOGRID 1 training cohort MACC1 mRNA levels were related to MACC1 protein levels from immunohistochemistry in FFPE sections; also analyzed for MMR. Chemotherapy-naïve pMMR patients were stratified by MACC1 mRNA and protein expression to establish risk groups based on recurrence-free survival (RFS). ..

View full abstract